Novartis receives EU approval for Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis

  • There are more than 1 million people living with multiple sclerosis (MS) in Europe1, Kesimpta® (ofatumumab) addresses the current unmet need for a high-efficacy disease-modifying therapy (DMT) that combines powerful efficacy and favorable safety profile with the flexibility of self-administration at home via the Sensoready® autoinjector pen2,3
  • Approval based on two Phase III ASCLEPIOS studies that met primary endpoints where …
/by

Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)

  • Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74

  • Broad expression of FAP demonstrated in tumors or in tumor stroma across many solid tumors1,2,3

  • Novartis Oncology continues to reimagine cancer care through development of robust radioligand therapy portfolio

Basel, March 30, 2021 — …

/by